{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:05:56Z","timestamp":1785477956079,"version":"3.56.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"7","funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["397423"],"award-info":[{"award-number":["397423"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0642_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the pediatric population at global level. Present study aims to assess the effect of <jats:sc>l<\/jats:sc>-carnitine supplementation on the NAFLD in children and adolescents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0642_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This randomized, triple-blind, placebo-controlled clinical trial was conducted in 2018\u20132019. Study was carried out in NAFLD participants (5\u201315 years). They were randomly assigned to receive either 50\u00a0mg\/kg\/day <jats:sc>l<\/jats:sc>-carnitine twice a day or identical placebo per day for three months. Liver enzymes and liver ultrasonography were assessed before and after the intervention. Both groups received similar consultation for lifestyle changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0642_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 55 participants completed the study, 30 patients in the <jats:sc>l<\/jats:sc>-carnitine group and 25 patients in placebo group. Mean changes of anthropometric measurements did not have significant differences between groups (p&gt;0.05). No significant differences in the mean changes of aspartate aminotransferase (AST) (p=0.82) and alanine aminotransferase (ALT) (p=0.76) levels were documented between two groups. Based on within-group analysis, there were significant changes in AST and ALT levels before and after the intervention in both groups. The sonographic grades of fatty liver were not significantly different between two groups before (p=0.94) and after intervention (p=0.93).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0642_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the present clinical trial, L-carnitine did not have significant effect on improving biochemical and sonographic markers of NAFLD in children and adolescents. Future studies are necessary to evaluate the applicability and efficacy of long-term <jats:sc>l<\/jats:sc>-carnitine supplementation to treatment of NAFLD in pediatric population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0642_abs_005\">\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>IRCT20170628034786N2.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0642","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T20:23:30Z","timestamp":1620073410000},"page":"897-904","source":"Crossref","is-referenced-by-count":19,"title":["Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial"],"prefix":"10.1515","volume":"34","author":[{"given":"Hossein","family":"Saneian","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran"},{"name":"Department of Pediatrics, Child Growth and Development Research Center , Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khalilian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motahar","family":"Heidari-Beni","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Child Growth and Development Research Center , Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Khademian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran"},{"name":"Department of Pediatrics, Child Growth and Development Research Center , Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Famouri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran"},{"name":"Department of Pediatrics, Child Growth and Development Research Center , Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Nasri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine , Isfahan University of Medical Sciences , Isfahan , Iran"},{"name":"Department of Pediatrics, Child Growth and Development Research Center , Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Hassanzadeh","sequence":"additional","affiliation":[{"name":"Department of Statistics and Epidemiology, School of Health , Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Kelishadi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Child Growth and Development Research Center , Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences , Isfahan , Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"2023040101233472685_j_jpem-2020-0642_ref_001","doi-asserted-by":"crossref","unstructured":"Wang, XJ, Malhi, H. Nonalcoholic fatty liver disease. Ann Intern Med 2018;169:ITC65\u201380. https:\/\/doi.org\/10.7326\/aitc201811060.","DOI":"10.7326\/IsTranslatedFrom_AITC201811060_Japanese"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_002","doi-asserted-by":"crossref","unstructured":"Kragh Petersen, S, Bilkei-Gorzo, O, Govaere, O, H\u00e4rtlova, A. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). Scand J Immunol 2020;92:e12971. https:\/\/doi.org\/10.1111\/sji.12971.","DOI":"10.1111\/sji.12971"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_003","doi-asserted-by":"crossref","unstructured":"Perumpail, BJ, Khan, MA, Yoo, ER, Cholankeril, G, Kim, D, Ahmed, A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017;23:8263\u201376. https:\/\/doi.org\/10.3748\/wjg.v23.i47.8263.","DOI":"10.3748\/wjg.v23.i47.8263"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_004","doi-asserted-by":"crossref","unstructured":"Carr, RM, Oranu, A, Khungar, V, Nonalcoholic fatty liver disease: pathophysiology and management. Gastroenterol Clin N Am 2016;45:639\u201352. https:\/\/doi.org\/10.1016\/j.gtc.2016.07.003.","DOI":"10.1016\/j.gtc.2016.07.003"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_005","doi-asserted-by":"crossref","unstructured":"Schwimmer, JB, Dunn, W, Norman, GJ, Pardee, PE, Middleton, MS, Kerkar, N, et al.. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010;138:1357\u201364.e2. https:\/\/doi.org\/10.1053\/j.gastro.2009.12.052.","DOI":"10.1053\/j.gastro.2009.12.052"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_006","doi-asserted-by":"crossref","unstructured":"Macabuag-Oliva, AM, Capellan, ML, Benitez, B. A comparison of the sensitivity and specificity of ultrasound elastography compared to liver ultrasound, ALT, and AST in the detection of fatty liver and fibrosis in patients with metabolic syndrome and type 2 diabetes mellitus. J ASEAN Fed Endocr Soc 2014;29:59\u201364. https:\/\/doi.org\/10.15605\/jafes.029.01.09.","DOI":"10.15605\/jafes.029.01.09"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_007","doi-asserted-by":"crossref","unstructured":"Worm, N. Beyond body weight-loss: dietary strategies targeting intrahepatic fat in NAFLD. Nutrients 2020;12:1316. https:\/\/doi.org\/10.3390\/nu12051316.","DOI":"10.3390\/nu12051316"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_008","doi-asserted-by":"crossref","unstructured":"Chalasani, N, Younossi, Z, Lavine, JE, Charlton, M, Cusi, K, Rinella, M, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","DOI":"10.1002\/hep.29367"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_009","doi-asserted-by":"crossref","unstructured":"Vos, MB, Abrams, SH, Barlow, SE, Caprio, S, Daniels, SR, Kohli, R, et al.. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319\u201334. https:\/\/doi.org\/10.1097\/mpg.0000000000001482.","DOI":"10.1097\/MPG.0000000000001482"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_010","doi-asserted-by":"crossref","unstructured":"Savic, D, Hodson, L, Neubauer, S, Pavlides, M. The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD). Nutrients 2020;12:2178. https:\/\/doi.org\/10.3390\/nu12082178.","DOI":"10.3390\/nu12082178"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_011","doi-asserted-by":"crossref","unstructured":"Salic, K, Gart, E, Seidel, F, Verschuren, L, Caspers, M, van Duyvenvoorde, W, et al.. Combined treatment with L-carnitine and nicotinamide riboside improves hepatic metabolism and attenuates obesity and liver steatosis. Int J Mol Sci 2019;20:4359. https:\/\/doi.org\/10.3390\/ijms20184359.","DOI":"10.3390\/ijms20184359"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_012","doi-asserted-by":"crossref","unstructured":"Kathirvel, E, Morgan, K, French, SW, Morgan, TR. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease. Nutr Res 2013;33:932\u201341. https:\/\/doi.org\/10.1016\/j.nutres.2013.08.001.","DOI":"10.1016\/j.nutres.2013.08.001"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_013","doi-asserted-by":"crossref","unstructured":"Mollica, G, Senesi, P, Codella, R, Vacante, F, Montesano, A, Luzi, L, et al.. L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Dig Liver Dis 2020;52:314\u201323. https:\/\/doi.org\/10.1016\/j.dld.2019.09.002.","DOI":"10.1016\/j.dld.2019.09.002"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_014","doi-asserted-by":"crossref","unstructured":"De Onis, M, Onyango, AW, Borghi, E, Siyam, A, Nishida, C, Siekmann, J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85:660\u20137. https:\/\/doi.org\/10.2471\/blt.07.043497.","DOI":"10.2471\/BLT.07.043497"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_015","doi-asserted-by":"crossref","unstructured":"Ma, X, Holalkere, NS, Kambadakone, RA, Mino-Kenudson, M, Hahn, PF, Sahani, DV. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics 2009;29:1253\u201377. https:\/\/doi.org\/10.1148\/rg.295085186.","DOI":"10.1148\/rg.295085186"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_016","doi-asserted-by":"crossref","unstructured":"Hamza, RT, Elkabbany, ZA, Shedid, AM, Hamed, AI, Ebrahim, AO. Serum chemerin in obese children and adolescents before and after L-carnitine therapy: relation to nonalcoholic fatty liver disease and other features of metabolic syndrome. Arch Med Res 2016;47:541\u20139. https:\/\/doi.org\/10.1016\/j.arcmed.2016.11.010.","DOI":"10.1016\/j.arcmed.2016.11.010"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_017","doi-asserted-by":"crossref","unstructured":"Zhou, M, Yang, N, Xing, X, Chang, D, Li, J, Deng, J, et al.. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:43. https:\/\/doi.org\/10.1186\/s12876-021-01615-w.","DOI":"10.1186\/s12876-021-01615-w"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_018","doi-asserted-by":"crossref","unstructured":"Mardinoglu, A, Ural, D, Zeybel, M, Yuksel, HH, Uhl\u00e9n, M, Bor\u00e9n, J. The potential use of metabolic cofactors in treatment of NAFLD. Nutrients 2019;11:1578. https:\/\/doi.org\/10.3390\/nu11071578.","DOI":"10.3390\/nu11071578"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_019","doi-asserted-by":"crossref","unstructured":"El-Agroudy, NN, Kurzbach, A, Rodionov, RN, O\u2019Sullivan, J, Roden, M, Birkenfeld, AL, et al.. Are lifestyle therapies effective for NAFLD treatment? Trends Endocrinol Metabol 2019;30:701\u20139. https:\/\/doi.org\/10.1016\/j.tem.2019.07.013.","DOI":"10.1016\/j.tem.2019.07.013"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_020","doi-asserted-by":"crossref","unstructured":"Abbasnezhad, A, Hasanavand, A, Falahi, E, Kashkooli, S, Asbaghi, O, Choghakhori, R. Effect of L-carnitine supplementation on lipid profiles of patients with liver disease: a systematic review and meta-analysis. Prev Nutr Food Sci 2020;25:124. https:\/\/doi.org\/10.3746\/pnf.2020.25.2.124.","DOI":"10.3746\/pnf.2020.25.2.124"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_021","doi-asserted-by":"crossref","unstructured":"Kelek, SE, Af\u015far, E, Ak\u00e7ay, G, Dan\u0131\u015fman, B, Aslan, M. Effect of chronic L-carnitine supplementation on carnitine levels, oxidative stress and apoptotic markers in peripheral organs of adult Wistar rats. Food Chem Toxicol 2019;134:110851. https:\/\/doi.org\/10.1016\/j.fct.2019.110851.","DOI":"10.1016\/j.fct.2019.110851"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_022","doi-asserted-by":"crossref","unstructured":"Li, J-L, Wang, Q-Y, Luan, H-Y, Kang, Z-C, Wang, C-B. Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha. J Biomed Sci 2012;19:32. https:\/\/doi.org\/10.1186\/1423-0127-19-32.","DOI":"10.1186\/1423-0127-19-32"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_023","doi-asserted-by":"crossref","unstructured":"Hamza, RT, Elkabbany, ZA, Shedid, AM, Hamed, AI, Ebrahim, AO. Serum chemerin in obese children and adolescents before and after L-carnitine therapy: relation to nonalcoholic fatty liver disease and other features of metabolic syndrome. Arch Med Res 2016;47:541\u20139. https:\/\/doi.org\/10.1016\/j.arcmed.2016.11.010.","DOI":"10.1016\/j.arcmed.2016.11.010"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_024","doi-asserted-by":"crossref","unstructured":"Somi, MH, Fatahi, E, Panahi, J, Havasian, MR. Data from a randomized and controlled trial of L-carnitine prescription for the treatment for non-alcoholic fatty liver disease. Bioinformation 2014;10:575\u20139. https:\/\/doi.org\/10.6026\/97320630010575.","DOI":"10.6026\/97320630010575"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_025","doi-asserted-by":"crossref","unstructured":"Thiagarajan, P, Chalmers, J, Ban, L, Grindlay, D, Aithal, GP. L-carnitine supplementation in non-alcoholic fatty liver disease: a systematic review and meta-analysis. World J Metaanal 2020;8:4\u201314. https:\/\/doi.org\/10.13105\/wjma.v8.i1.4.","DOI":"10.13105\/wjma.v8.i1.4"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_026","doi-asserted-by":"crossref","unstructured":"Abolfathi, M, Mohd-Yusof, BN, Hanipah, ZN, Mohd Redzwan, S, Yusof, LM, Khosroshahi, MZ. The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Compl Ther Med 2020;48:102273. https:\/\/doi.org\/10.1016\/j.ctim.2019.102273.","DOI":"10.1016\/j.ctim.2019.102273"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_027","doi-asserted-by":"crossref","unstructured":"Malaguarnera, M, Gargante, MP, Russo, C, Antic, T, Vacante, M, Malaguarnera, M, et al.. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis\u2014a randomized and controlled clinical trial. Am J Gastroenterol 2010;105:1338\u201345. https:\/\/doi.org\/10.1038\/ajg.2009.719.","DOI":"10.1038\/ajg.2009.719"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_028","doi-asserted-by":"crossref","unstructured":"Xia, Y, Li, Q, Zhong, W, Dong, J, Wang, Z, Wang, C. L-carnitine ameliorated fatty liver in high-calorie diet\/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndrome 2011;3:31. https:\/\/doi.org\/10.1186\/1758-5996-3-31.","DOI":"10.1186\/1758-5996-3-31"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_029","doi-asserted-by":"crossref","unstructured":"Mollica, G, Senesi, P, Codella, R, Vacante, F, Montesano, A, Luzi, L, et al.. L-carnitine supplementation attenuates NAFLD progression and cardiac dysfunction in a mouse model fed with methionine and choline-deficient diet. Dig Liver Dis 2020;52:314\u201323. https:\/\/doi.org\/10.1016\/j.dld.2019.09.002.","DOI":"10.1016\/j.dld.2019.09.002"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_030","doi-asserted-by":"crossref","unstructured":"Salic, K, Gart, E, Seidel, F, Verschuren, L, Caspers, M, van Duyvenvoorde, W, et al.. Combined treatment with L-carnitine and nicotinamide riboside improves hepatic metabolism and attenuates obesity and liver steatosis. Int J Mol Sci 2019;20:4359. https:\/\/doi.org\/10.3390\/ijms20184359.","DOI":"10.3390\/ijms20184359"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_031","doi-asserted-by":"crossref","unstructured":"Malaguarnera, M, Gargante, MP, Russo, C, Antic, T, Vacante, M, Malaguarnera, M, et al.. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis\u2013a randomized and controlled clinical trial. Am J Gastroenterol 2010;105:1338\u201345. https:\/\/doi.org\/10.1038\/ajg.2009.719.","DOI":"10.1038\/ajg.2009.719"},{"key":"2023040101233472685_j_jpem-2020-0642_ref_032","doi-asserted-by":"crossref","unstructured":"Samulak, JJ, Sawicka, AK, Hartmane, D, Grinberga, S, Pugovics, O, Lysiak-Szydlowska, W, et al.. L-carnitine supplementation increases trimethylamine-N-oxide but not markers of atherosclerosis in healthy aged women. Ann Nutr Metab 2019;74:11\u20137. https:\/\/doi.org\/10.1159\/000495037.","DOI":"10.1159\/000495037"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0642\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0642\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T19:59:18Z","timestamp":1680379158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0642\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4,19]]},"published-print":{"date-parts":[[2021,7,27]]}},"alternative-id":["10.1515\/jpem-2020-0642"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0642","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}